康艾注射液联合化疗治疗老年肺癌临床疗效及不良反应观察  

Observation on the Clinical Efficacy and Adverse Reactions of Kang'ai Injection Combined with Chemotherapy in the Treatment of Lung Cancer in the Elderly Patients

作　　者：侯宝青[1] 

机构地区：[1]山东省胸科医院呼吸内科,山东济南250014

出　　处：《中外医疗》2014年第31期25-26,共2页China & Foreign Medical Treatment

摘　　要：目的探讨康艾注射液联合化疗治疗老年肺癌临床疗效及不良反应发生情况。方法选取2013年1—12月收治的90例老年肺癌患者,随机分为两组,观察组和对照组,每组各45例。对照组患者采用单一化疗治疗,观察组患者联合应用化疗和康艾注射液,比较两组患者治疗2个月后的临床疗效和不良反应发生率。结果观察组治疗2个月后疾病控制率95.6%(43/45),对照组为82.2%(37/45),差异有统计学意义(P<0.01);两组患者在客观缓解率差异无统计学意义(P>0.05);观察组总稳定率(88.9%)明显高于对照组(60%),差异有统计学意义(P<0.05);观察组共出现20例不良反应,对照组出现43例,差异有统计学意义(P<0.05)。结论应用康艾注射液联合化疗治疗老年肺癌有助于提高临床疗效,有效控制疾病的稳定性,改善患者的生活质量,减少不良反应的发生,值得在临床上进一步推广。Objective To investigate the clinical efficacy and adverse reactions of Kang＇ai injection combined with chemotherapy in the treatment of lung cancer in the elderly patients. Methods 90 elderly patients with lung cancer admitted from January 2013 to December 2013 were selected and randomly divided into two groups, the observation group and the control group with 45 patients in each. Patients in the control group were treated by chemotherapy alone, and patients in the observation group were treated by chemotherapy combined with Kang＇ai injection. After 2 months of treatment, the clinical efficacy and incidence of adverse reactions were compared between the two groups. Results After 2 months of treatment, the disease control rate of the observation group was 95.6%（43/45）, and that of the control group was 82.2%（37/45） with significant difference（P〈0.01）; the difference in objective remission rate between the two groups was not statistically significant（P〈0.05）; the total stable rate of the observation group（88.9%） was significantly higher than that of the control group（60%）, the difference was statistically significant（P〉0.05）; adverse reactions occurred in 20 cases in the observation group, 43 cases in the control group, the difference between the groups was significant（P〈0.05）. Conclusion Kang＇ai injection combined with chemotherapy in the treatment of lung cancer in the elderly helps to improve the clinical efficacy and quality of life of the patients, effectively control the stability of the disease, reduce the incidence of adverse reactions, so it is worthy of further promotion in clinical practice.

关 键 词：康艾注射液 化疗 老年肺癌 临床疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]